In This Article:
Over the last 7 days, the United States market has dropped 2.6%, yet it has risen by 24% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of fluctuating performance and anticipated growth, identifying high growth tech stocks involves looking at companies with innovative technologies and strong potential for future expansion.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 24.13% | 24.28% | ★★★★★★ |
| Ardelyx | 22.51% | 54.38% | ★★★★★★ |
| Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
| Clene | 61.16% | 59.11% | ★★★★★★ |
| Alnylam Pharmaceuticals | 21.24% | 56.34% | ★★★★★★ |
| TG Therapeutics | 30.06% | 45.28% | ★★★★★★ |
| Blueprint Medicines | 22.63% | 55.38% | ★★★★★★ |
| Travere Therapeutics | 28.68% | 62.50% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
AC Immune
Simply Wall St Growth Rating: ★★★★★☆
Overview: AC Immune SA is a clinical stage biopharmaceutical company focused on discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases related to protein misfolding, with a market cap of $267.14 million.
Operations: The company specializes in creating therapeutic and diagnostic solutions for neurodegenerative diseases linked to protein misfolding. It operates as a clinical stage biopharmaceutical entity with a focus on innovation in this niche field.
AC Immune's recent executive reshuffling underscores a strategic emphasis on enhancing its R&D capabilities, particularly in AI and digital technologies, which are crucial for advancing its biotech innovations. The company has demonstrated robust revenue growth at 30.5% annually, outpacing the industry average. Moreover, AC Immune's focus on developing treatments for neurodegenerative diseases is highlighted by the positive interim results from its ACI-7104.056 trial for Parkinson’s disease and ACI-24.060 for Down syndrome-related Alzheimer’s, both showing promising safety profiles and immunogenic responses. This progress is pivotal as it aligns with the fast-track designation received from the FDA, potentially accelerating the path to market and benefiting patients sooner.
-
Click to explore a detailed breakdown of our findings in AC Immune's health report.
-
Assess AC Immune's past performance with our detailed historical performance reports.
CareDx
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CareDx, Inc. focuses on developing and commercializing diagnostic solutions for transplant patients and caregivers globally, with a market cap of $1.15 billion.